STOCK TITAN

Vivani Medical Stock Price, News & Analysis

VANI Nasdaq

Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.

Vivani Medical Inc (VANI) is a preclinical-stage biopharmaceutical innovator developing long-term implantable drug delivery systems through its proprietary NanoPortal™ technology. This page provides authorized news updates and press releases about the company's advancements in chronic disease treatment solutions.

Investors and industry observers will find timely updates on clinical development milestones, strategic partnerships, and regulatory progress. Our curated news collection focuses on factual reporting of implantable device innovations, research collaborations, and therapeutic application developments across Vivani's Biopharm and Neuromodulation divisions.

Key content categories include updates on NanoPortal™ technology enhancements, preclinical trial results, intellectual property developments, and executive leadership announcements. All information is verified through primary sources to ensure compliance with financial disclosure standards.

Bookmark this page for direct access to Vivani Medical's official communications, presented in chronological order with clear date stamps. For comprehensive understanding of the company's technology platform, review our detailed company profile alongside these news updates.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.27%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.66%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
Rhea-AI Summary

Vivani Medical, Inc. (NASDAQ: VANI) announced the NIH's approval of year 5 funding for the Early Feasibility Clinical Study of the Orion Visual Cortical Prosthesis, amounting to $1 million, completing a $6.4 million five-year grant. This funding will support Cortigent, Inc., a subsidiary focusing on providing artificial vision to profoundly blind individuals. Approximately 82,000 Americans are estimated to be profoundly blind, and the results of the study are expected in mid-2023. The Orion device, designed to convert images into electrical pulses for the brain's visual cortex, has received FDA Breakthrough Device designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags

FAQ

What is the current stock price of Vivani Medical (VANI)?

The current stock price of Vivani Medical (VANI) is $1.15 as of June 18, 2025.

What is the market cap of Vivani Medical (VANI)?

The market cap of Vivani Medical (VANI) is approximately 70.5M.
Vivani Medical

Nasdaq:VANI

VANI Rankings

VANI Stock Data

70.50M
30.19M
48.98%
8.41%
0.48%
Biotechnology
Electromedical & Electrotherapeutic Apparatus
Link
United States
ALAMEDA